




Supplementary Figure 1: Funnel Plot of the studies examining bisphosphonates and UGI cancer




Supplementary Figure 2.1: Meta-analysis of risk of oesophageal cancer with any bisphosphonate – sensitivity analysis (1)




Supplementary Figure 2.2: Meta-analysis of risk of oesophageal cancer with any bisphosphonate – sensitivity analysis (2)




Supplementary Figure 2.3: Meta-analysis of risk of oesophageal cancer with any bisphosphonate – sensitivity analysis (3)




Supplementary Figure 4.1: Meta-analysis of risk of oesophageal cancer with alendronate – sensitivity analysis (1)




Supplementary Figure 4.2: Meta-analysis of risk of oesophageal cancer with alendronate – sensitivity analysis (2)




Supplementary Figure 4.3: Meta-analysis of risk of oesophageal cancer with alendronate – sensitivity analysis (3)



Supplementary Figure 5: Meta-analysis of risk of gastric cancer with alendronate



Supplementary Figure 6: Meta-analysis of cohort studies – UGI cancer and bisphosphonates



Supplementary Figure 7: Meta-analysis of case control studies – UGI cancer and bisphosphonates

